Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Hematology
Study Phase : Phase III
Recipient : Shenyang Sunshine Pharmaceutical Co Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 27, 2016
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Hematology
Highest Development Status : Phase III
Recipient : Shenyang Sunshine Pharmaceutical Co Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cicletanine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : IndiPharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2016
Lead Product(s) : Cicletanine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : IndiPharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Hematology
Study Phase : Phase IV
Recipient : Shenyang Sunshine Pharmaceutical Co Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 14, 2015
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Recipient : Shenyang Sunshine Pharmaceutical Co Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
